Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00444678
Status:
COMPLETED
Last Update Posted:
2020-04-03
First Post:
2007-03-07
Brief Title:
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Sponsor:
NYU Langone Health
Organization:
NYU Langone Health
Organization Data
Organization:
NYU Langone Health
Class:
OTHER
Study ID:
NYU 04-10 H11817
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
NYU Langone Health
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |
| Eli Lilly and Company | INDUSTRY |